MITSUBISHI TANABE PHARMA CORPORATION

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Efficacy and Safety Study of MP-513 in Combination With Sulfonylurea in Patients With Type 2 Diabetes

Phase 3

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Teneli / Teneli + SU
Drug: Placebo / Teneli (Teneligliptin) + SU (Sulfonylurea)

First Posted Date: 2009-09-10

Last Posted Date: 2014-05-08

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 194

Registration Number: NCT00974090

Efficacy and Safety of MP-513 in Combination With Metformin in Patients With Type 2 Diabetes

Phase 2

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: MP-513 Medium Dose and Metformin
Drug: MP-513 Low Dose and Metformin
Drug: MP-513 Lowest Dose and Metformin
Drug: Placebo and Metformin
Drug: MP-513 High Dose and Metformin

First Posted Date: 2009-09-03

Last Posted Date: 2014-09-01

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 448

Registration Number: NCT00971243

Safety, Pharmacokinetics and Efficacy Study of MP-214 in Patients With Schizophrenia

Phase 2

Completed

Conditions: Schizophrenia

Interventions: Drug: Cariprazine 6 mg
Drug: Cariprazine 3 mg
Drug: Cariprazine 12.5 mg

First Posted Date: 2009-03-17

Last Posted Date: 2021-04-12

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 34

Registration Number: NCT00862992

Locations: 🇯🇵
Hoyu Hospital, Kure-City, Hiroshima-ken, Japan

Clinical Management of Argatroban in Patients With Heparin Induced Thrombocytopenia Type II

Phase 2

Completed

Conditions: Heparin-induced Thrombocytopenia Type II

Interventions: Drug: argatroban

First Posted Date: 2009-03-13

Last Posted Date: 2016-08-01

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 20

Registration Number: NCT00861692

Efficacy and Safety Study of MCI-196 Versus Simvastatin for Dyslipidaemia in Chronic Kidney Disease (CKD) Subjects on Dialysis

Phase 3

Completed

Conditions: Chronic Kidney Disease

Interventions: Drug: MCI-196
Drug: Simvastatin
Drug: Placebo of Simvastatin
Drug: Placebo of MCI-196

First Posted Date: 2009-03-10

Last Posted Date: 2014-12-30

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 260

Registration Number: NCT00858637

Safety and Pharmacokinetics of MCI-186 in Subjects With Acute Ischemic Stroke

Phase 2

Completed

Conditions: Acute Ischemic Stroke (AIS)

Interventions: Drug: MCI-186
Drug: Placebo

First Posted Date: 2009-01-14

Last Posted Date: 2014-05-12

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 36

Registration Number: NCT00821821

Locations: 🇬🇧
Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, United Kingdom
🇳🇱
Erasmus Medical Center, Rotterdam, Netherlands
🇫🇮
Helsinki University Central Hospital, Helsinki, Finland

Efficacy and Safety of Increased Dose of TA-650 (Infliximab) in Patients With Crohn's Disease (CD)

Phase 3

Completed

Conditions: Crohn's Disease

Interventions: Drug: TA-650

First Posted Date: 2008-12-10

Last Posted Date: 2018-02-09

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 39

Registration Number: NCT00805766

Locations: 🇯🇵
Investigational site, Kyushu, Japan

Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Chronic Hepatitis C Who Have Not Achieved an Undetectable HCV RNA Level With Previous Interferon Based Therapy

Phase 3

Completed

Conditions: Hepatitis C

Interventions: Drug: MP-424
Drug: Ribavirin
Drug: Peginterferon Alfa-2b

First Posted Date: 2008-10-28

Last Posted Date: 2014-05-02

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 32

Registration Number: NCT00781274

Locations: 🇯🇵
Toranomon Hospital, Kawasaki City, Takatsu-ku, Japan

Efficacy and Safety of MP-424, Peginterferon Alfa-2b, and Ribavirin in Patients With Chronic Hepatitis C Who Relapsed After Previous Interferon Based Therapy

Phase 3

Completed

Conditions: Chronic Hepatitis C

Interventions: Drug: MP-424
Drug: Ribavirin
Drug: Peginterferon Alfa-2b

First Posted Date: 2008-10-28

Last Posted Date: 2014-05-02

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 109

Registration Number: NCT00780910

Locations: 🇯🇵
Toranomon Hospital, Kawasaki City, Takatsu-ku, Japan

Efficacy and Safety of MP-424/Peginterferon Alfa-2b/Ribavirin Combination in Treatment-Naïve Patients With Chronic Hepatitis C

Phase 3

Completed

Conditions: Hepatitis C

Interventions: Drug: MP-424
Drug: Ribavirin
Drug: Peginterferon Alfa-2b

First Posted Date: 2008-10-27

Last Posted Date: 2014-05-02

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 189

Registration Number: NCT00780416

Locations: 🇯🇵
Toranomon Hospital, Kawasaki City, Takatsu-ku, Japan

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy